Current preclinical and clinical data indicate that inhibitors of the PI3K/Akt/mTOR pathway in combination with other anticancer therapies might have greater utility to suppress the progression of PC and its resistance to chemotherapy. This evidence concerns the gene MTOR and pachyonychia congenita.